Ocular pharmacokinetic/pharmacodynamic modeling for timolol in rabbits using a telemetry system

被引:8
|
作者
Sakanaka, Koji [1 ,2 ]
Kawazu, Kouichi [1 ]
Tomonari, Masahide [2 ]
Kitahara, Takashi [2 ]
Nakashima, Mikiro [3 ]
Nishida, Koyo [3 ]
Nakamura, Junzo [3 ]
Sasaki, Hitoshi [2 ]
Higuchi, Shun [4 ]
机构
[1] Santen Pharmaceut Co Ltd, Nara Res & Dev Ctr, Ikoma 6300101, Japan
[2] Nagasaki Univ, Sch Med, Dept Hosp Pharm, Nagasaki 8528501, Japan
[3] Nagasaki Univ, Grad Sch Biomed Sci, Nagasaki 8528521, Japan
[4] Kyushu Univ, Grad Sch Pharmaceut Sci, Higashi Ku, Fukuoka 8128582, Japan
关键词
pharmacokinetic; pharmacodynamic; eye; timolol; telemetry system;
D O I
10.1248/bpb.31.970
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We have established an ocular pharmacokinetic/pharmacodynamic (PK/PD) model for a P-adrenergic antagonist, timolol, after instillation into rabbits. Timolol concentrations were determined by HPLC in the tear fluid, aqueous humor, cornea, and iris-ciliary body after instillation or ocular injection into the anterior chamber of the eye in rabbits. In addition, intraocular pressure (IOP) measurement was performed after instillation of timolol by a telemetry system, which was able to obtain detailed IOP data automatically. The PK/PD parameters were estimated by fitting the concentration-time profiles and the ocular hypotensive effect-time profiles using MULTI (RUNGE) program. The PK model consisted of six compartments and the PD model included aqueous humor dynamics based on an action mechanism of timolol, which causes lowering of IOP by suppressing aqueous humor production. The PK/PD model described well the concentration-time profiles and the ocular hypotensive effect-time profiles after instillation of timolol. This study is the first trial to develop an ocular PK/PD model for timolol after instillation. This model can predict both the drug concentrations in various ocular tissues and the ocular hypotensive effect after instillation of timolol.
引用
收藏
页码:970 / 975
页数:6
相关论文
共 50 条
  • [31] Targeted Ocular Drug Delivery with Pharmacokinetic/Pharmacodynamic Considerations
    Shen, Jie
    Lu, Guang Wei
    Hughes, Patrick
    PHARMACEUTICAL RESEARCH, 2018, 35 (11)
  • [32] PHARMACOKINETIC AND PHARMACODYNAMIC MODELING OF NEUTROPENIA FOR LURBINECTEDIN
    Fernandez Teruel, C.
    de Miguel Lillo, B.
    Fudio Munoz, S.
    Soto Matos-Pita, A.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 20 - 21
  • [33] Targeted Ocular Drug Delivery with Pharmacokinetic/Pharmacodynamic Considerations
    Jie Shen
    Guang Wei Lu
    Patrick Hughes
    Pharmaceutical Research, 2018, 35
  • [34] Pharmacokinetic and Pharmacodynamic Modeling of Romiplostim in Animals
    Wojciech Krzyzanski
    Liviawati Sutjandra
    Juan Jose Perez-Ruixo
    Bethlyn Sloey
    Andrew T. Chow
    Yow-Ming Wang
    Pharmaceutical Research, 2013, 30 : 655 - 669
  • [35] SIMULTANEOUS PHARMACOKINETIC AND PHARMACODYNAMIC MODELING OF PHYSOSTIGMINE
    UNNI, LK
    SOMANI, SM
    FEDERATION PROCEEDINGS, 1986, 45 (03) : 204 - 204
  • [36] PHARMACOKINETIC/PHARMACODYNAMIC MODELING - WHAT IT IS - COMMENTARY
    SHEINER, LB
    JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1987, 15 (05): : 553 - 555
  • [37] PHARMACOKINETIC-PHARMACODYNAMIC MODELING IN PAIN
    Loetsch, J.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 14 - 14
  • [38] Population pharmacokinetic and pharmacodynamic modeling of norvancomycin
    J. Zhang
    Y. Zhang
    Y. Shi
    J. Rui
    J. Yu
    G. Cao
    J. Wu
    European Journal of Clinical Microbiology & Infectious Diseases, 2008, 27 : 275 - 284
  • [39] Pharmacokinetic-pharmacodynamic modeling:: Why?
    Pérez-Urizar, J
    Granados-Soto, V
    Flores-Murrieta, FJ
    Castañeda-Hernández, G
    ARCHIVES OF MEDICAL RESEARCH, 2000, 31 (06) : 539 - 545
  • [40] PHARMACOKINETIC AND PHARMACODYNAMIC MODELING OF DOXAZOSIN AND TRIMAZOSIN
    MEREDITH, PA
    ELLIOTT, HL
    KELMAN, AW
    REID, JL
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1982, 12 (02) : 26 - 26